Compare Apple Inc (AAPL) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Apple Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Apple Inc trades at $301.5 (market cap $4.45T), while State Street SPDR S&P Biotech ETF trades at $159.35. The key difference: Apple Inc pays a 0.35% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Apple Inc nearer its low. Which is the better fit depends on your goals.
| AAPL | XBI | |
|---|---|---|
Market Cap | $4.45T | — |
Volume | 100,358,844 | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $340.08 | $164.28 |
52-Week Low | $224.90 | $86.92 |
Enterprise Value | $4.47T | — |
Dividend Yield | 0.35% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AAPL trades at $301.42, down 2.22% on the day, with a bearish technical signal. The stock shows strong fundamentals, including a 26.91% net income margin and consistent earnings beats. Recent news highlights Apple's leadership in smartphone shipments and AI potential through its 2.5 billion active devices, though it faces challenges from union disputes and potential earnings pressure.
Outlook remains positive with a consensus price target of $337.63, implying 12% upside. Risks include weaker iPhone sales, regulatory scrutiny from EU fines, and competitive pressures. Analyst sentiment is bullish (63.64% buy ratings), but technical weakness and near-term headwinds warrant caution.
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Apple Inc
Apple Inc. designs, manufactures, and markets personal computers and related personal computing and mobile communication devices along with a variety of related software, services, peripherals, and networking solutions. Apple sells its products worldwide through its online stores, its retail stores, its direct sales force, third-party wholesalers, and resellers.
Read more on AAPL →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
